These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 20981642)
1. Relationship between baseline severity of depression and antidepressant treatment outcome. Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Kronmüller K; Holsboer F; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Riedel M; Möller HJ Pharmacopsychiatry; 2011 Jan; 44(1):27-32. PubMed ID: 20981642 [TBL] [Abstract][Full Text] [Related]
2. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression. Nelson JC J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463 [No Abstract] [Full Text] [Related]
3. Relationship between the Hamilton Depression Rating Scale and the Montgomery-Asberg Depression Rating Scale in depressed elderly: a meta-analysis. Heo M; Murphy CF; Meyers BS Am J Geriatr Psychiatry; 2007 Oct; 15(10):899-905. PubMed ID: 17911366 [TBL] [Abstract][Full Text] [Related]
4. Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression. Furukawa TA; Akechi T; Azuma H; Okuyama T; Higuchi T J Clin Psychopharmacol; 2007 Oct; 27(5):531-4. PubMed ID: 17873700 [No Abstract] [Full Text] [Related]
5. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961 [TBL] [Abstract][Full Text] [Related]
6. Effectiveness of antidepressant treatments in pre-menopausal versus post-menopausal women: a pilot study on differential effects of sex hormones on antidepressant effects. Pae CU; Mandelli L; Kim TS; Han C; Masand PS; Marks DM; Patkar AA; Steffens DC; De Ronchi D; Serretti A Biomed Pharmacother; 2009 Mar; 63(3):228-35. PubMed ID: 18502089 [TBL] [Abstract][Full Text] [Related]
7. The Maudsley Staging Method for treatment-resistant depression: prediction of longer-term outcome and persistence of symptoms. Fekadu A; Wooderson SC; Markopoulou K; Cleare AJ J Clin Psychiatry; 2009 Jul; 70(7):952-7. PubMed ID: 19457299 [TBL] [Abstract][Full Text] [Related]
8. Confounding by severity and indication in observational studies of antidepressant effectiveness. Patten SB Can J Clin Pharmacol; 2008; 15(2):e367-71. PubMed ID: 18840922 [TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552 [TBL] [Abstract][Full Text] [Related]
10. Do estradiol levels influence on the cognitive function during antidepressant treatments in post-menopausal women with major depressive disorder? A comparison with pre-menopausal women. Pae CU; Mandelli L; Han C; Ham BJ; Masand PS; Patkar AA; Steffens DC; De Ronchi D; Serretti A Neuro Endocrinol Lett; 2008 Aug; 29(4):500-6. PubMed ID: 18766158 [TBL] [Abstract][Full Text] [Related]
11. White matter hyperintensity progression and late-life depression outcomes. Taylor WD; Steffens DC; MacFall JR; McQuoid DR; Payne ME; Provenzale JM; Krishnan KR Arch Gen Psychiatry; 2003 Nov; 60(11):1090-6. PubMed ID: 14609884 [TBL] [Abstract][Full Text] [Related]
12. Major depression: the importance of clinical characteristics and treatment response to prognosis. Katon W; Unützer J; Russo J Depress Anxiety; 2010; 27(1):19-26. PubMed ID: 19798766 [TBL] [Abstract][Full Text] [Related]
14. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city]. Mouchabac S; Ferreri M; Cabanac F; Bitton M Encephale; 2003; 29(5):438-44. PubMed ID: 14615693 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831 [TBL] [Abstract][Full Text] [Related]
18. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
19. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Adler DA; Bungay KM; Wilson IB; Pei Y; Supran S; Peckham E; Cynn DJ; Rogers WH Gen Hosp Psychiatry; 2004; 26(3):199-209. PubMed ID: 15121348 [TBL] [Abstract][Full Text] [Related]
20. Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: an open label study. Akkaya C; Sivrioglu EY; Akgoz S; Eker SS; Kirli S Hum Psychopharmacol; 2006 Jul; 21(5):337-45. PubMed ID: 16856215 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]